Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAF V600E Unresectable or Metastatic Melanoma”

14 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 14 of 14 results

Large-scale testing (Phase 3)Study completedNCT01909453
What this trial is testing

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

Who this might be right for
Melanoma
Pfizer 921
Early research (Phase 1)Study completedNCT05003622
What this trial is testing

Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors

Who this might be right for
BRAF V600E Unresectable or Metastatic MelanomaBRAF V600E Metastatic NSCLCMelanoma
Pierre Fabre Medicament 3
Large-scale testing (Phase 3)Study completedNCT01006980
What this trial is testing

Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 675
Early research (Phase 1)Ended earlyNCT03878719
What this trial is testing

Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma

Who this might be right for
Melanoma
Pfizer 1
Large-scale testing (Phase 3)Study completedNCT01584648
What this trial is testing

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Who this might be right for
Melanoma
Novartis Pharmaceuticals 423
Large-scale testing (Phase 3)Active Not RecruitingNCT04657991
What this trial is testing

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

Who this might be right for
Melanoma
Pfizer 257
Early research (Phase 1)Study completedNCT01767454
What this trial is testing

Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

Who this might be right for
Solid Tumours
GlaxoSmithKline 38
Testing effectiveness (Phase 2)Active Not RecruitingNCT06784648
What this trial is testing

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

Who this might be right for
Melanoma MetastaticMelanoma of SkinMelanoma BRAF V600E/K Mutated+7 more
BioInvent International AB 35
Early research (Phase 1)Ended earlyNCT02097225
What this trial is testing

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Who this might be right for
BRAF V600E Mutation PresentBRAF V600K Mutation PresentMetastatic Malignant Solid Neoplasm+7 more
National Cancer Institute (NCI) 22
Large-scale testing (Phase 3)Study completedNCT01597908
What this trial is testing

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Who this might be right for
Melanoma
Novartis Pharmaceuticals 704
Not applicableNo Longer AvailableNCT02416232
What this trial is testing

Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

Who this might be right for
Melanoma
GlaxoSmithKline
Large-scale testing (Phase 3)Study completedNCT01689519
What this trial is testing

A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 495
Testing effectiveness (Phase 2)Ended earlyNCT02410863
What this trial is testing

Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma

Who this might be right for
Malignant Melanoma
Prof. Dr. med. Dirk Schadendorf 10
Testing effectiveness (Phase 2)Ended earlyNCT01586195
What this trial is testing

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Who this might be right for
Malignant Melanoma
Genentech, Inc. 31